Navigation Links
Nabriva Therapeutics Announces Appointment of New CEO
Date:7/2/2008

VIENNA, Austria, July 3 /PRNewswire/ -- Nabriva Therapeutics, a specialist in antibiotics development, announces that Dr. George Golumbeski has been appointed as Chief Executive Officer of the Company.

Dr. Golumbeski brings to the team nearly twenty years of industry experience serving most recently as Vice President of Business Development, Licensing & Strategy for the oncology business unit at Novartis. In this position he was responsible for the full array of business development activities leading several transactions which have resulted in projects currently in Phase III studies. While at Novartis, Dr. Golumbeski also served as a member of the Executive Committee which oversees overall oncology business performance. Prior to his tenure at Novartis, he led transactions which have resulted in two products that have been approved or are in registration in the US and the EU.

"I am excited to join Nabriva at this important stage of its growth. The Company's highly differentiated compounds have the potential to address the significant need for new classes of effective antibiotics. Furthermore, the team at Nabriva is highly experienced with a deep understanding and enthusiasm for the development of novel antibiotics," commented Dr. Golumbeski.

David Chiswell, Chair of the Supervisory Board, added, "We are pleased to welcome George to the team. His leadership skills combined with his strategic and business development insight will help position Nabriva as one of the leading specialist companies in antibiotics development."

About Nabriva Therapeutics:

Headquartered in Vienna, Nabriva Therapeutics is engaged in the discovery and development of innovative antibacterial agents addressing unmet medical need in the hospital and community setting. The company has two compounds currently in clinical trials and expects to have a third compound enter clinical trials later this year. The lead compound, BC-3205, is a parenterally and orall
'/>"/>

SOURCE Nabriva Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
2. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
3. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
4. Tobira Therapeutics Inc. Announces Senior Management Team
5. Duska Therapeutics Obtains Standard & Poors Listing
6. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
7. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
8. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
9. Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
10. Barrier Therapeutics to Merge Into Stiefel Laboratories
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... As a leading provider of telehealth ... release of their infographic - " 8 New ... goal was to leverage an information graphic to ... 3.0 and mHealth.The infographic features a list of ... the fitness industry in unimaginable ways; turning science ...
(Date:6/18/2013)... 18, 2013 Inflamax Research Inc., ... Concept and Phase I-IV clinical trials, announced today ... Northern Air Environmental Technologies (NAET), a specialty air ... monitoring, and servicing of mobile Environmental Exposure Chambers ... trials. , Inflamax Research has ...
(Date:6/18/2013)... Earlier this year, Google announced the new ‘enhanced ... directly impacts the core component of the product, the campaign, ... sweeping updates since its inception in October of 2000. ... very informative article on the subject.. , ... enhanced campaigns . Only recently, a date of ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 NuView Life ... imaging and in vitro diagnostic (IVD) biomarkers, today announced ... novel urine screen in development for the early detection ... presented in an oral presentation at the 2013 Annual ... Imaging (SNMMI) in Vancouver, Canada on Sunday, June 9th. ...
Breaking Biology Technology:MeMD, Inc Releases Infographic Featuring the Top Eight Technologies that are Revolutionizing Health and Fitness Today 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 2Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 3NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI 2NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI 3
... CITY, June 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. ... global biopharmaceutical company focused on endocrine therapy and ... previously announced registered direct offering of US$10 million ... share purchase warrants to certain institutional investors. AEterna ...
... June 24 International Products Corporation,s ( ... performing filter membrane compatibility and performance ... the ability to evaluate any type of membrane media, from ... President, Kathy Wyrofsky. "Our goal is to be able ...
... ... that it provided the Helsinn Group with the transaction advisory support for the successful ... on Monday. Full details of this transaction can be found at http://www.prnewswire.co.uk/cgi/news/release?id=259822 . ... Oxford, UK ...
Cached Biology Technology:AEterna Zentaris Receives US$10 Million from Institutional Investors 2AEterna Zentaris Receives US$10 Million from Institutional Investors 3International Products Corp.'s Lab Offers Filter Membrane Compatibility and Studies 2PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group 2
(Date:6/18/2013)... been awarded a $394,300 grant from the Tarrant ... flow in the new facilities of the 150-mile ... associate professor of civil engineering, will investigate the ... the water in an effort to eliminate biological ... Adding monochloramine is widely practiced throughout the United ...
(Date:6/18/2013)... National Institutes of Health has awarded $12.7 million ... selection of pharmaceutical industry compounds to explore new ... Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. The ... for Existing Molecules, is led by the National ... by the NIH Common Fund. , The process ...
(Date:6/18/2013)... 5% and 10% of breast and ovarian cancers are ... tumours are attributable to inherited mutations from the parents ... with these mutations, PARP inhibitors, which are currently in ... a new option for personalised cancer treatment, an alternative ... a fraction of these patients generate resistance to the ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
... demonstrated the role of a gene important to the ... requires coordination of differentiation of immature neural cells with ... Until now, the mechanisms regulating these distinct cellular activities ... be published in the Feb. 15 issue of Development. ...
... hunting among chimpanzees is a group effort, key males, known ... are more likely to initiate a hunt, and hunts rarely ... The findings, which appear in the current issue of Animal ... to hunt for food, and how individual variation among chimpanzees ...
... more sensitive and more accurate than conventional imaging methods ... to a UCLA study that is among the first ... study has important implications for patients. If conventional imaging ... that in fact are working and study participants may ...
Cached Biology News:Trainor Lab characterizes gene essential for prenatal development of nervous system 2Key 'impact hunters' catalyze hunting among male chimpanzees 2Key 'impact hunters' catalyze hunting among male chimpanzees 3Positron emission tomography superior to standard evaluation tools in measuring treatment response 2Positron emission tomography superior to standard evaluation tools in measuring treatment response 3
... Microarrays designed for proteomic scale kinase ... activities, and drug discovery research built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive Protein Kinase Substrate - Peptide ...
... Western blotting is a commonly used technique ... protein samples are electrophoresed on SDS-PAGE and ... or nylon, where they are probed with ... which allow reuse of Southern and Northern ...
... for immunological studies, vaccine development, and ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive Epitope Peptide ... Content Probe content is completely ...
... built on the flexible and powerful ... microarrays are available as part of ... Custom Probe Content ... Thousands of customer specified peptide sequences ...
Biology Products: